Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop
the growth of tumor cells by blocking blood flow to the tumor. Giving temsirolimus together
with bevacizumab may be a better way to block tumor growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of temsirolimus
when given together with bevacizumab and to see how well it works in treating patients with
hormone-resistant metastatic prostate cancer that did not respond to chemotherapy.